Ixmyelocel-T

Phase 3Completed

1 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Critical Limb Ischemia

Conditions

Critical Limb Ischemia

Trial Timeline

Feb 1, 2012 → Mar 25, 2014

NCT ID

NCT01483898

About Ixmyelocel-T

Ixmyelocel-T is a phase 3 stage product being developed by Vericel for Critical Limb Ischemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01483898. Target conditions include Critical Limb Ischemia.

What happened to similar drugs?

4 of 8 similar drugs in Critical Limb Ischemia were approved

Approved (4) Terminated (2) Active (2)

✅DaptomycinMerckApproved

✅Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.AmgenApproved

🔄Apixaban + ASA + Clopidogrel 75mgPfizerPhase 3

✅Colchicine (Colcrys®) + placebo + allopurinolRegeneron PharmaceuticalsApproved

🔄Rilonacept 80 mg + Rilonacept 160 mgRegeneron PharmaceuticalsPhase 3

❌Remodulin® (treprostinil sodium) InjectionUnited TherapeuticsPhase 3

❌Olimel (5.7%E / N9E)BaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01670981	Phase 2	Completed	Feb 20, 2013	Mar 7, 2018	Ischemic Dilated Cardiomyopathy (IDCM)
NCT01483898	Phase 3	Completed	Feb 1, 2012	Mar 25, 2014	Critical Limb Ischemia
NCT01020968	Phase 2	Completed	Dec 1, 2009	Dec 5, 2013	Dilated Cardiomyopathy
NCT00765518	Phase 2	Completed	Sep 1, 2008	Sep 5, 2012	Dilated Cardiomyopathy
NCT00505219	Phase 3	Completed	Sep 1, 2007	Dec 1, 2010	Osteonecrosis

Competing Products

13 competing products in Critical Limb Ischemia

See all competitors

Product	Company	Stage	Hype Score
Daptomycin	Merck	Approved	43
Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose	Merck	Phase 1	29
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.	Amgen	Approved	39
intensive insulin therapy to maintain normoglycemia	Novo Nordisk	Phase 2	35
Midazolam + Dexmedetomidine	Pfizer	Pre-clinical	26
Apixaban + ASA + Clopidogrel 75mg	Pfizer	Phase 3	36
Colchicine (Colcrys®) + placebo + allopurinol	Regeneron Pharmaceuticals	Approved	43
Rilonacept 80 mg + Rilonacept 160 mg	Regeneron Pharmaceuticals	Phase 3	40
treprostinil dienthanolmine sustained release + Placebo	United Therapeutics	Phase 2	32
Remodulin® (treprostinil sodium) Injection	United Therapeutics	Phase 3	29
Olimel (5.7%E / N9E)	Baxter	Phase 3	29
Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E	Baxter	Approved	44
RJX + Placebo	ICON plc.	Phase 1	26